New CAR-T therapy aims to tackle tough childhood leukemia
NCT ID NCT07244406
First seen Jan 04, 2026 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This phase 2 trial tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cells. The main goal is to see how many patients achieve remission three months after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Senl_B19 autologous anti-CD19 CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for children and young adults with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong
This is a phase 2 trial with only 59 participants, so results are still early. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.